Of note, for HRD patients, in addition to PARPis, we suggested that targeting FGFR1+PDGFRΒ+ myCAFs by TKIs, targeting CD8+Tex by ICB therapy (anti‐PDCD1/CTLA4/LAG‐3/TIGIT) and targeting Tregs by CCR8 or CTLA‐4 antagonists/ TNFRSF4 agonists may be effective. Here, PDGFRB is linked to hypoparathyroidism-retardation-dysmorphism syndrome.